리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 02월
페이지 정보:영문 465 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 miRNA 시퀀싱 및 어세이 시장은 2030년까지 7억 6,310만 달러에 이를 전망
2024년에 3억 7,900만 달러로 추정된 miRNA 시퀀싱 및 어세이 시장은 2030년에는 7억 6,310만 달러에 이를 것으로 예측되며, 분석 기간인 2024-2030년간 CAGR은 12.4%로 성장할 전망입니다. 본 보고서에서 분석한 부문 중 하나인 miRNA 시퀀싱&어세이 제품은 CAGR 11.9%를 나타내고, 분석 기간 종료시에는 6억 350만 달러에 이를 것으로 예측됩니다. miRNA 시퀀싱&어세이 서비스 부문의 성장률은 분석 기간에 CAGR 14.3%를 나타낼 전망입니다.
미국 시장은 1억 330만 달러로 추정, 중국은 CAGR 16.5%로 성장 예측
미국의 miRNA 시퀀싱 및 어세이 시장은 2024년에 1억 330만 달러에 이른 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 1억 5,950만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년간 CAGR은 16.5%를 나타낼 전망입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 9.1%와 11.0%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 9.8%로 성장할 것으로 예측됩니다.
세계의 miRNA 시퀀싱 및 어세이 시장 - 주요 동향과 촉진요인 정리
왜 miRNA 시퀀싱이 생물의학 연구에서 전례 없는 주목을 받는가?
마이크로RNA(miRNA) 시퀀싱은 다양한 질병에서 유전자 조절과 그 의미를 이해하는 데 중요한 도구로 부상하고 있습니다. 암, 신경 퇴행성 질환, 심혈관 질환과 같은 복잡한 질병이 증가함에 따라 연구자들은 바이오마커와 치료 표적을 확인하기 위해 miRNA 프로파일링에 점점 더 많은 관심을 기울이고 있습니다. 유전자 발현을 조절하고 세포 과정에 관여하는 miRNA의 능력은 정밀의료에서 매우 중요합니다. 유전체학에 대한 투자 증가와 차세대 시퀀싱(NGS) 기술의 발전은 miRNA 시퀀서의 채택에 더욱 박차를 가하고 있습니다. 또한, 생명과학 연구에 자금을 지원하는 공공 및 민간 이니셔티브는 최첨단 miRNA 분석 기술 개발을 가속화하고 있습니다. 개인 맞춤형 의료에 대한 관심이 높아지는 것도 miRNA 시퀀싱이 개인 맞춤형 치료에 필요한 정확성과 특이성을 제공한다는 점에서 수요 증가에 기여하고 있습니다.
기술의 발전은 miRNA 분석 시장에 어떤 혁명을 불러일으키고 있는가?
miRNA 분석 시장은 시퀀싱 플랫폼과 바이오인포매틱스 툴의 혁신에 힘입어 기술적 변혁기를 맞이하고 있습니다. 단일 세포 RNA 시퀀싱과 같은 첨단 시퀀싱 기술을 통해 연구자들은 miRNA의 발현과 질병 경로에서 miRNA의 역할에 대한 보다 상세한 통찰력을 얻을 수 있게 되었습니다. 또한, 데이터 분석에 인공지능과 머신러닝을 통합하여 복잡한 miRNA 데이터 세트의 해석을 간소화하여 연구자와 임상의가 보다 쉽게 사용할 수 있는 기술을 제공합니다. 더 높은 민감도와 특이성을 포함한 분석 키트의 혁신은 miRNA 검출의 신뢰성을 높이고 있습니다. 또한, 여러 miRNA를 동시에 분석할 수 있는 멀티플렉스 분석법의 개발로 대규모 연구에 소요되는 비용과 시간을 크게 절감할 수 있게 되었습니다. 이러한 발전은 miRNA 분석의 전반적인 효율성을 향상시킬 뿐만 아니라 진단, 신약개발, 치료제 개발의 응용 가능성을 넓히고 있습니다.
시장 확대에 있어 헬스케어 용도의 역할은?
헬스케어 분야에서의 miRNA 시퀀싱의 적용은 시장 확대의 주요 요인입니다. 예를 들어, 종양학에서 miRNA 프로파일링은 암을 조기에 발견하고, 환자의 예후를 예측하고, 질병의 진행을 모니터링할 수 있는 진단 검사 개발에 활용되고 있습니다. 마찬가지로 신경학에서는 알츠하이머병, 파킨슨병 및 기타 신경 퇴행성 질환의 바이오마커로 miRNA가 연구되고 있습니다. 진단학 외에도, miRNA 분석은 치료학에서도 주목을 받고 있으며, 많은 임상시험에서 표적 치료에의 활용을 모색하고 있습니다. 산전 선별검사, 감염 진단, 면역 반응 모니터링에 miRNA 시퀀싱을 통합하는 것은 그 다재다능함을 더욱 입증하고 있습니다. 만성 질환의 유병률 증가, 조기 발견 및 정밀의료에 대한 전 세계적인 관심은 헬스케어 분야에서 miRNA 시퀀싱 및 분석에 대한 수요를 유지할 것으로 예상됩니다.
miRNA 시퀀싱 및 분석 시장의 성장 원동력은?
miRNA 시퀀싱 및 분석 시장의 성장은 여러 요인에 의해 주도되고 있으며, 이는 생물 의학 연구 및 헬스케어의 발전에 있어 매우 중요한 역할을 강조하고 있습니다. 암 및 만성 질환의 유병률 증가로 인해 miRNA 기반 진단 및 치료제에 대한 수요가 크게 증가하고 있으며, NGS 기술의 발전으로 인해 miRNA 시퀀싱이 더욱 정확하고 비용 효율적이며 널리 사용 가능해져 시장 확산에 더욱 박차를 가하고 있습니다. 개인 맞춤형 의료에 대한 관심 증가와 신약 개발 파이프라인에서 miRNA 프로파일링의 통합이 증가하는 것도 주요 기여 요인입니다. 또한, 비침습적 액체 생검에서 miRNA의 적용이 확대되고 질병 메커니즘을 규명하는 데 있어 miRNA의 역할이 확대되면서 현대 의학에서 miRNA의 관련성이 높아지고 있습니다. 이러한 촉진요인들이 결합하여 시장 상황은 견조한 성장을 향해 나아가고 있으며, 유전체 연구와 임상 전망을 재구성하고 있습니다.
부문
제품 및 서비스(miRNA 시퀀싱 및 분석 제품, miRNA 시퀀싱 및 분석 서비스), 기술(합성기술에 의한 시퀀싱, 올리고뉴클레오티드 드라이게이션 및 검출(SOLiD) 기술에 의한 시퀀싱, 나노포어 시퀀싱 기술, 싱어 시퀀싱 기술, 단일 분자 실시간(SMRT) 시퀀싱 기술), 용도(암 용도, 폴리글루타민 질환 용도, 자가면역질환 용도, 조현병 용도, 기타 용도), 최종 용도(연구/학술기관 최종 용도, 제약/바이오 기업 최종 용도, 기타 최종 용도)
조사 대상 기업 예(주요 27개사)
Abcam Plc
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Lexogen
Meridian Bioscience, Inc.
New England Biolabs, Inc.
Norgen Biotek Corp.
QIAGEN NV
System Biosciences, LLC
Takara Bio Inc
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global miRNA Sequencing and Assays Market to Reach US$763.1 Million by 2030
The global market for miRNA Sequencing and Assays estimated at US$379.0 Million in the year 2024, is expected to reach US$763.1 Million by 2030, growing at a CAGR of 12.4% over the analysis period 2024-2030. miRNA Sequencing & Assay Products, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$603.5 Million by the end of the analysis period. Growth in the miRNA Sequencing & Assay Services segment is estimated at 14.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$103.3 Million While China is Forecast to Grow at 16.5% CAGR
The miRNA Sequencing and Assays market in the U.S. is estimated at US$103.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$159.5 Million by the year 2030 trailing a CAGR of 16.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.
Global miRNA Sequencing and Assays Market - Key Trends & Drivers Summarized
Why Is miRNA Sequencing Gaining Unprecedented Attention in Biomedical Research?
MicroRNA (miRNA) sequencing has emerged as a critical tool in understanding gene regulation and its implications in various diseases. With the rise in complex diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions, researchers are increasingly turning to miRNA profiling to identify biomarkers and therapeutic targets. The ability of miRNAs to regulate gene expression and play a role in cellular processes makes them invaluable in precision medicine. The growing investment in genomics and advancements in next-generation sequencing (NGS) technologies have further fueled the adoption of miRNA sequencing. Moreover, public and private initiatives to fund life sciences research are accelerating the development of cutting-edge miRNA assay technologies. The increasing interest in personalized medicine is also contributing to the demand, as miRNA sequencing provides the precision and specificity required to tailor treatments.
How Are Technological Advancements Revolutionizing the miRNA Assays Market?
The miRNA assays market is undergoing a technological transformation, driven by innovations in sequencing platforms and bioinformatics tools. Advanced sequencing technologies, such as single-cell RNA sequencing, are enabling researchers to obtain more detailed insights into miRNA expression and its role in disease pathways. Additionally, the integration of artificial intelligence and machine learning in data analysis has simplified the interpretation of complex miRNA datasets, making the technology more accessible to researchers and clinicians. Innovations in assay kits, including higher sensitivity and specificity, have enhanced the reliability of miRNA detection. Furthermore, the development of multiplexed assays that can simultaneously analyze multiple miRNAs has significantly reduced the cost and time associated with large-scale studies. These advancements not only improve the overall efficiency of miRNA analysis but also broaden its applicability in diagnostics, drug discovery, and therapeutic development.
What Role Do Healthcare Applications Play in Expanding the Market?
The application of miRNA sequencing in healthcare is a major driver of its market expansion. In oncology, for instance, miRNA profiling is being used to develop diagnostic tests that can detect cancer at an early stage, predict patient outcomes, and monitor disease progression. Similarly, in neurology, miRNAs are being investigated as biomarkers for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. In addition to diagnostics, miRNA assays are gaining traction in therapeutics, with numerous clinical trials exploring their use in targeted treatments. The integration of miRNA sequencing in prenatal screening, infectious disease diagnostics, and immune response monitoring further demonstrates its versatility. The increasing prevalence of chronic diseases and the global focus on early detection and precision medicine are expected to sustain the demand for miRNA sequencing and assays in the healthcare sector.
What Is Driving Growth in the miRNA Sequencing and Assays Market?
The growth in the miRNA sequencing and assays market is driven by several factors that underscore its pivotal role in advancing biomedical research and healthcare. The rising prevalence of cancer and chronic diseases has significantly increased the demand for miRNA-based diagnostics and therapeutics. Advancements in NGS technologies have made miRNA sequencing more accurate, cost-effective, and widely accessible, further fueling market adoption. The growing focus on personalized medicine and the increasing integration of miRNA profiling in drug discovery pipelines are also key contributors. Moreover, the expanding application of miRNAs in non-invasive liquid biopsies and their role in understanding disease mechanisms have boosted their relevance in modern medicine. Together, these drivers are propelling the miRNA sequencing and assays market toward robust growth, reshaping the landscape of genomic research and clinical practice.
SCOPE OF STUDY:
The report analyzes the miRNA Sequencing and Assays market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
miRNA Sequencing and Assays - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Next-Generation Sequencing Technologies Drive miRNA Analysis Growth
Rising Research Activities in Cancer and Genetic Disorders Propel miRNA Sequencing Demand
Increasing Use of miRNA Sequencing in Biomarker Discovery Drives Market Expansion
Growth in Personalized Medicine Fuels Demand for miRNA Assays
Role of miRNA in Early Diagnosis of Diseases Boosts Market Adoption
Rising Applications of miRNA Sequencing in Drug Development Drive Innovation
Emergence of Cost-Effective miRNA Sequencing Platforms Expands Accessibility
Integration of AI in miRNA Analysis Enhances Research Efficiency
Demand for High-Throughput Screening Technologies Propels miRNA Sequencing Market
Rising Focus on Non-Invasive Diagnostic Techniques Drives Adoption of miRNA Assays
Government and Private Funding for Genomic Research Fuels Market Growth
Expansion of miRNA Applications in Neurological and Cardiovascular Disorders Propels Demand
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World miRNA Sequencing and Assays Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for miRNA Sequencing and Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for miRNA Sequencing & Assay Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for miRNA Sequencing & Assay Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for miRNA Sequencing & Assay Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for miRNA Sequencing & Assay Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for miRNA Sequencing & Assay Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for miRNA Sequencing & Assay Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Autoimmune Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Autoimmune Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Autoimmune Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Schizophrenia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Schizophrenia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Schizophrenia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Polyglutamine Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Polyglutamine Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Polyglutamine Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Sequencing by Synthesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Sequencing by Synthesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Sequencing by Synthesis Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Nanopore Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Nanopore Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: World 15-Year Perspective for Nanopore Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: World 15-Year Perspective for Sanger Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 47: World Recent Past, Current & Future Analysis for Single Molecule Real-time (SMRT) Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 48: World Historic Review for Single Molecule Real-time (SMRT) Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: World 15-Year Perspective for Single Molecule Real-time (SMRT) Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 50: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: USA 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 56: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: USA Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: USA 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 59: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: USA Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: USA 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
CANADA
TABLE 62: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Canada 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 65: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Canada Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Canada 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 68: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Canada Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Canada 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 71: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Canada Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Canada 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
JAPAN
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 74: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Japan 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 77: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Japan Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Japan 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 80: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Japan Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Japan 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 83: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Japan Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Japan 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
CHINA
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 86: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: China Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: China 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 89: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: China Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: China 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 92: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: China Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: China 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 95: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: China Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: China 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
EUROPE
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 98: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for miRNA Sequencing and Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Europe 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Europe Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Europe 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 104: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Europe Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Europe 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 107: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Europe Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Europe 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 110: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Europe Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Europe 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
FRANCE
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 113: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: France Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: France 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 116: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: France Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: France 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 119: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: France Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: France 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 122: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: France Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: France 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
GERMANY
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 125: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Germany Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: Germany 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 128: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Germany Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Germany 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 131: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Germany Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Germany 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 134: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Germany Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Germany 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
ITALY
TABLE 137: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Italy Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Italy 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 140: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Italy Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Italy 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 143: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Italy Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Italy 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 146: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Italy Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Italy 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
UNITED KINGDOM
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 149: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: UK Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: UK 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 152: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: UK Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: UK 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 155: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: UK Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: UK 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 158: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: UK Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: UK 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
SPAIN
TABLE 161: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Spain Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Spain 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 164: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Spain Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Spain 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 167: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Spain Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Spain 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 170: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Spain Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: Spain 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
RUSSIA
TABLE 173: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Russia Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: Russia 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 176: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Russia Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: Russia 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 179: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Russia Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: Russia 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 182: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Russia Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: Russia 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Europe Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Europe Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Europe Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Europe Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
ASIA-PACIFIC
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 198: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Asia-Pacific Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
AUSTRALIA
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 212: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Australia Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 214: Australia 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 215: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Australia Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 217: Australia 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 218: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Australia Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 220: Australia 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 221: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Australia Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 223: Australia 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
INDIA
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 224: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: India Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 226: India 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 227: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: India Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 229: India 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 230: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: India Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 232: India 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 233: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: India Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 235: India 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 236: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: South Korea Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 238: South Korea 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 239: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: South Korea Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 241: South Korea 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 242: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: South Korea Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 244: South Korea 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 245: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 246: South Korea Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 247: South Korea 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 250: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 253: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 256: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 259: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
LATIN AMERICA
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 260: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 261: Latin America Historic Review for miRNA Sequencing and Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 262: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 263: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Latin America Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 265: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 266: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Latin America Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 268: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 269: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Latin America Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 271: Latin America 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 272: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Latin America Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 274: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 275: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Argentina Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 277: Argentina 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 278: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Argentina Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 280: Argentina 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 281: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Argentina Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 283: Argentina 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 284: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: Argentina Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 286: Argentina 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
BRAZIL
TABLE 287: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: Brazil Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 289: Brazil 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 290: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: Brazil Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 292: Brazil 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 293: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Brazil Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 295: Brazil 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 296: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Brazil Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 298: Brazil 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
MEXICO
TABLE 299: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Mexico Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 301: Mexico 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 302: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Mexico Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 304: Mexico 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 305: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Mexico Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 307: Mexico 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 308: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Mexico Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 310: Mexico 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 312: Rest of Latin America Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 313: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 315: Rest of Latin America Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 316: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 318: Rest of Latin America Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 319: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 321: Rest of Latin America Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 322: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
MIDDLE EAST
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 323: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 324: Middle East Historic Review for miRNA Sequencing and Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 325: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 326: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 327: Middle East Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 328: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 329: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 330: Middle East Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 331: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 332: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 333: Middle East Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 334: Middle East 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 335: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 336: Middle East Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 337: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
IRAN
TABLE 338: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 339: Iran Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 340: Iran 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 341: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 342: Iran Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 343: Iran 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 344: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 345: Iran Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 346: Iran 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 347: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 348: Iran Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 349: Iran 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
ISRAEL
TABLE 350: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 351: Israel Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 352: Israel 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 353: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 354: Israel Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 355: Israel 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 356: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 357: Israel Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 358: Israel 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 359: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 360: Israel Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 361: Israel 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 363: Saudi Arabia Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 364: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 366: Saudi Arabia Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 367: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 369: Saudi Arabia Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 370: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 372: Saudi Arabia Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 373: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 374: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 375: UAE Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 376: UAE 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 377: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 378: UAE Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 379: UAE 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 380: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 381: UAE Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 382: UAE 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 383: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 384: UAE Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 385: UAE 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 387: Rest of Middle East Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 388: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 390: Rest of Middle East Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 391: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 393: Rest of Middle East Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 394: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 396: Rest of Middle East Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 397: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
AFRICA
miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 398: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 399: Africa Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 400: Africa 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
TABLE 401: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 402: Africa Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 403: Africa 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
TABLE 404: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 405: Africa Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 406: Africa 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
TABLE 407: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 408: Africa Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 409: Africa 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030